CagriSema

News

ADA: Lilly's weight-loss reveal, and wannabes display wares

Lilly reveals more details of its retatrutide obesity and diabetes studies, plus trial updates from Zealand/Roche, Pfizer, Novo Nordisk, and Sciwind.

News

After CagriSema blow, Novo reveals data for obesity 'triple'

Novo Nordisk's triple-action obesity therapy UBT251, licensed in a $2bn deal last year, achieved almost 20% weight loss in a mid-stage trial.

News

Cartoon graphic of a woman with glasses holding thought bubbles in the palm of either hand, one with a check and one with a cross

Head-to-head trial dents Novo Nordisk's obesity hopes

Novo Nordisk slumps as its two-drug combination for weight loss, CagriSema, performs less well than Eli Lilly's rival Zepbound in a comparative trial.

News

Novo Nordisk's CagriSema tops Ozempic in diabetes trial

Novo Nordisk is considering filing CagriSema for diabetes, in addition to obesity, after it outperformed Ozempic in a head-to-head study.

News

Lilly points to long-lasting weight loss with orforglipron

Lilly breaks new ground for oral GLP-1 agonists with data showing it can help patients keep weight off after treatment with injectable therapies.

News

ADA: Novo continues effort to rehabilitate CagriSema

Novo Nordisk's phase 3 data for CagriSema at ADA raises questions about how weight loss data in obesity trials are interpreted.

ADA: Lilly's weight-loss reveal, and wannabes display wares

After CagriSema blow, Novo reveals data for obesity 'triple'

Head-to-head trial dents Novo Nordisk's obesity hopes

Novo Nordisk's CagriSema tops Ozempic in diabetes trial

Lilly points to long-lasting weight loss with orforglipron

ADA: Novo continues effort to rehabilitate CagriSema

ASCO 2026: Chinese firms take a front seat in oncology, with...

Discover a new era of healthcare panel engagement: Grounded ...

CagriSema

Editor's Picks